Genetix Group plc, along with its subsidiaries, is engaged in the design, development, manufacture and marketing of automated systems, services and consumables for cell biology, cytogenetics, pathology, proteomic and genomic research worldwide. The biopharmaceutical family of products include the ClonePixFL and associated reagents, which are used to identify the antibody clones that form the basis of pharmaceutical drugs. The ClonePix FL is also used to identify high-yielding cell lines for a customer’s production process. Its Cytovision systems are used worldwide for both pre and post natal genetic testing, and identifying certain forms of cancer, such as leukemia. Its Ariol system is used to image tissue samples from patients. Its wholly owned subsidiaries include Genetix Limited, Genescreen Limited, Genpak Limited, Genetix GmbH and Genetix KK. In April 2009, the Company acquired SlidePath Limited. In January 2010, Danaher Corporation acquired 97% interest in the Company.

Antigenics was founded in 1994 and is headquartered in Lexington, Massachusetts. Antigenics Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its products include Oncophage (vitespen), a patient-specific therapeutic cancer vaccine registered for use in the Russia Federation, as well as under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease. The company tested Oncophage in phase 3 clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and phase 1 and phase 2 clinical trials for various indications, as well as in phase 2 clinical trial for the treatment of recurrent glioma, a type of brain cancer. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is used in various vaccines under development in trials for diseases, such as hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer's disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for the treatment of solid malignancies and B-cell lymphomas. The company was formerly known as Antigenics L.L.C. and changed its name to Antigenics, Inc. in February 2000.

Interleukin Genetics, Inc. was founded in 1986 and is headquartered in Waltham, Massachusetts. Interleukin Genetics, Inc., together with its subsidiaries, focuses on developing, acquiring, and commercializing personalized health products that help individuals improve and maintain their health through preventive measures in the United States and internationally. It conducts, researches, develops, markets, and sells genetic test panels primarily in inflammatory and metabolic areas to provide insight into health, wellness, and disease. The company markets and distributes genetic tests under the GENSONA brand, through a strategic partnership with Alticor; and PST tests through sales and marketing partners to dentists and periodontists. It offers genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. The company has research collaborations with the University of Sheffield, Tufts University, New York University, Harvard University, the Mayo Clinic, California Pacific Medical Center, Boston University, the University of Arkansas, Tongji Medical College, University of North Carolina, and Yonsei University.

BioSpecifics Technologies Corp. company was founded in 1957 and is headquartered in Lynbrook, New York. BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase for multiple indications in the United States. The company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase known as XIAFLEX for clinical indications in dupuytren's disease, peyronie's disease, and frozen shoulder. The XIAFLEX is under phase IIb clinical trial for the treatment of peyronie's disease. BioSpecifics Technologies also focuses on the development of collagenase for various other clinical indications, including lipomas and cellulite.

Palatin Technologies, Inc. company was founded in 1986 and is based in Cranbury, New Jersey. Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The company's products under development include PL-3994, a peptide mimetic natriuretic peptide receptor A agonist for the treatment of heart failure; Bremelanotide, a peptide melanocortin receptor agonist for the treatment of sexual dysfunction, targeting female sexual dysfunction and erectile dysfunction in patients non-responsive to current therapies; and PL-6983, a peptide melanocortin receptor agonist for the treatment of female sexual dysfunction. Its products in development also comprise melanocortin receptor-based compounds for treatment of obesity, diabetes, and related metabolic syndrome; and NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection. Palatin Technologies, Inc. has a licensing and research collaboration agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome.

Sanofi Pasteur helps you guard against getting sick in the first place. The company is the US vaccines division of French drugmaker Sanofi-Aventis. It makes vaccines that protect against such infectious diseases as influenza, polio, and meningitis. Some of its top sellers are flu vaccines, childhood combination vaccines, and adult booster shots. It also makes travelers' vaccines that keep globetrotters safe from typhoid, cholera, yellow fever, and the like. Projects in development include improved vaccines for influenza, preventative vaccines for HIV and dengue fever, and therapeutic vaccines for cancer.

Abbott GmbH wants to cure what ails you. A subsidiary of Abbott Labs, the company has production facilities in four German cities. The Wiesbaden facility produces biopharmaceuticals used to treat rheumatoid arthritis and HIV/AIDS, as well as hospital and nutritional products. It also houses the company's diagnostics sales department. The Ludwigshafen complex (one of Abbott's largest pharmaceutical production sites outside the US) is home to Abbott Labs' European clinical trials, high-tech drug production, and R&D operations. Wetzlar houses Abbott Vascular Management while Rangendingen houses a vascular instrument manufacturing plant where balloon catheters, stents, and stent delivery systems are made.

Protalix BioTherapeutics, Inc. ompany was founded in 1993 and is based in Carmiel, Israel. Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States. Its lead product candidate includes prGCD, a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme for the treatment of Gaucher disease, which is in Phase III clinical trial. The company also develops PRX-102, a proprietary alpha Galactosidase enzyme for the treatment of Fabry disease, a genetic lysosomal storage disorder in humans, the symptoms of which involve the accumulation of lipids in the cells of the kidneys, heart, and other organs; a proprietary plant cell-based acetylcholinestrase and its molecular variants for use in various therapeutic and prophylactic indications, including a Biodefense program; and an organophosphate-based pesticide treatment program. Protalix BioTherapeutics, Inc. has strategic collaboration with Teva Pharmaceutical Industries, Ltd. for the development and manufacturing of two proteins using the company's ProCellEx protein expression system; and Yeda Research and Development Company Limited to design Glucocerebrosidase for the treatment of Gaucher disease, as well as has a licensing agreement with Icon Genetics AG to license Icon's amplification technology for utilization in the expression of its products.

Allon Therapeutics Inc. company's primary focus is on developing treatments for Alzheimer's and other neurodegenerative diseases that lead to memory loss and cognitive impairment. Its lead candidate AL-108 is a nasal spray that has shown some efficacy in clinical trials in treating the symptoms of patients with amnestic mild cognitive impairment, a precursor to Alzheimer's. Allon has collaborations with the National Institute on Aging, the Alzheimer's Disease Cooperative Study, the Institute for the Study of Aging, and the Tel Aviv University.

Dow Pharmaceutical Sciences company researches and develops topical dermatological pharmaceutical and biotech products for external clients. It works to formulate the gel, ointment, or cream that will carry a client's drug, assesses its effectiveness, manufactures and packages product candidates for clinical trials, and provides regulatory affairs consulting. It provides contract research services through its Solano Clinical Research division in the US and its Bioskin subsidiary in Europe. Dow Pharmaceutical Sciences also develops dermatology products on a proprietary basis. The company is owned by Valeant Pharmaceuticals.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.